Phase 1 Platinum-Resistant Ovarian Carcinoma Clinical Trials
6 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–6 of 6 trials
Recruiting
Phase 1
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Recurrent Endometrial CarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)65 enrolled14 locationsNCT05950464
Recruiting
Phase 1
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Recurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma
National Cancer Institute (NCI)42 enrolled27 locationsNCT04633239
Recruiting
Phase 1
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Ovarian CancerOvarian CarcinomaRecurrent Platinum-Resistant Ovarian Carcinoma+1 more
Elizabeth Stover, MD, PhD30 enrolled3 locationsNCT06964009
Recruiting
Phase 1
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Metastatic Endometrial CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8+8 more
National Cancer Institute (NCI)42 enrolled6 locationsNCT05691504
Recruiting
Phase 1
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic12 enrolled1 locationNCT06483048
Recruiting
Phase 1
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
Platinum-Resistant Ovarian Carcinoma
City of Hope Medical Center33 enrolled1 locationNCT05225363